Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
78 participants
INTERVENTIONAL
2019-09-18
2020-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Before and after of 8 week intervention, 24-hour ambulatory blood pressure monitoring will be done and fasting venous blood sample will be taken to measure plasma lipids. In addition, 24-hour urine will be collected to measure its sodium content and estimate sodium intake.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Barberry
Daily consumption of barberry in powder form.
berberis vulgaris=barberry
10 grams of barberry powder will be consumed daily for 8 weeks.
placebo
Daily consumption of placebo powder.
Placebo
Placebo powder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
berberis vulgaris=barberry
10 grams of barberry powder will be consumed daily for 8 weeks.
Placebo
Placebo powder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age between 20-65 years
* having elevated BP (129/ \< 85) and known hypertensive patients on medical treatment
* at least one other classical cardiovascular disease risk factors, including hyperlipidemia or diabetes mellitus
Exclusion Criteria
* BMI\> 30
* patients on nitrates
* high doses of statins consumption (Atorvastatin\>40 mg/day or Rosuvastatin\>20 mg/day)
* consumption of vitamins or minerals supplements during past month
* Chronic kidney disease stage 4 or 5
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javad Nasrollahzadeh
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rajaei Cardiovascular, Medical & Research Center
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Emamat H, Zahedmehr A, Asadian S, Nasrollahzadeh J. The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial. BMC Complement Med Ther. 2022 Mar 7;22(1):59. doi: 10.1186/s12906-022-03539-8.
Emamat H, Zahedmehr A, Asadian S, Tangestani H, Nasrollahzadeh J. Effect of barberry (Berberis vulgaris) consumption on blood pressure, plasma lipids, and inflammation in patients with hypertension and other cardiovascular risk factors: study protocol for a randomized clinical trial. Trials. 2020 Nov 27;21(1):986. doi: 10.1186/s13063-020-04918-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
895
Identifier Type: -
Identifier Source: org_study_id